COMMUNIQUÉS West-GlobeNewswire

-
INNATE PHARMA : Updated results that support advancement of IPH4102 in refractory Sézary syndrome at ASH 2018
03/12/2018 -
INNATE PHARMA : ASH, présentation de résultats d'IPH4102 chez les patients présentant un syndrome de Sézary réfractaire et poursuite du développement en phase II dans les lymphomes de type T
03/12/2018 -
BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting
03/12/2018 -
Hybrigenics (ALHYG) : Moonstone Investments a soumis une proposition de transaction, sous conditions suspensives.
03/12/2018 -
CAPS® Teams with Kit Check to Add Serialized Radio Frequency Identification (RFID) Tags on Pre-Filled Syringes
03/12/2018 -
Exeter Hospital joins North American Partners in Anesthesia
03/12/2018 -
Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH
03/12/2018 -
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
03/12/2018 -
NICOX : Number of voting rights as of November 30. 2018
03/12/2018 -
NICOX : Nombre de droits de vote au 30 novembre 2018
03/12/2018 -
Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors
03/12/2018 -
Ossur Hf : Transactions in relation to share buyback program
03/12/2018 -
Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS)
03/12/2018 -
Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
03/12/2018 -
Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation
03/12/2018 -
GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile
03/12/2018 -
Medtronic Announces First Patient Treated in TERMINATE AF Clinical Trial
03/12/2018 -
Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps in Executing ONS-5010 Clinical and Regulatory Strategy
03/12/2018 -
Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome
03/12/2018
Pages